Geneception (now Skyline Therapeutics) R&D center launches in Zhangjiang Science City, equipped with cutting-edge gene therapy platforms
August 17, 2020

Shanghai, China, August 17, 2020 – Geneception (now Skyline Therapeutics) celebrated the opening of its new R&D center in Shanghai, a key project in Pudong’s Zhangjiang Science City. Skyline’s R&D center is a 70,000-square-feet, built-to-suit facility dedicated to innovative research and the development of gene therapies that can help address patients’ needs worldwide.


Skyline’s Shanghai-based R&D center, which has been fully operational since May 2020, is equipped with advanced viral vector research platforms and capabilities. The adeno associated virus (AAV) platforms that are being established in-house support innovative research activities including discovery, in-vitro biology, a histology lab, next-generation sequencing, bioinformatics, in-vivo pharmacology, as well as upstream process development and analytical development.


Established in late 2019, Skyline is dedicated to the discovery, development and delivery of innovative gene therapies. The newly launched R&D center is part of the firm’s strategic plan of building a fully integrated gene therapy platform from discovery to CMC, a pioneering setup to be in the industry.


With a focus on being a leader in the rapidly advancing field of gene therapy, Skyline has gathered a world-class team of scientific experts who are bringing their industry knowledge and experience to the development of innovative, high-quality gene therapy products.


The company raised $150 million in its first run of financing with support from a number of top-tier international investors with successful track records in helping to build top quality firms, including Eight Roads, F-Prime Capital, Eli Lilly Asia Fund, Hillhouse Capital, Sequoia Capital, and Arch Venture.